Precigen (PGEN) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	PRECIGEN, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PGEN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		208,150,021
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 9,067	$ 36,423
Restricted cash	82,443	0
Short-term investments	62,260	72,240
Receivables
Trade, less allowance for credit losses of $184 as of September 30, 2022 and December 31, 2021	1,175	1,341
Related parties, less allowance for credit losses of $0 as of September 30, 2022 and $1,509 December 31, 2021	19	73
Other	1,260	566
Inventory	219	326
Prepaid expenses and other	6,363	5,471
Current assets held for sale	0	40,188
Total current assets	162,806	156,628
Long-term investments	0	48,562
Property, plant and equipment, net	7,611	8,599
Intangible assets, net	42,416	52,291
Goodwill	36,713	37,554
Right-of-use assets	8,828	9,990
Other assets	871	936
Noncurrent assets held for sale	0	45,296
Total assets	259,245	359,856
Current liabilities
Accounts payable	4,201	3,112
Accrued compensation and benefits	5,792	7,856
Other accrued liabilities	11,685	7,817
Deferred revenue	76	1,490
Current portion of long-term debt	82,069	52
Current portion of lease liabilities	1,041	1,393
Related party payables	0	74
Current liabilities held for sale	0	12,851
Total current liabilities	104,864	34,645
Long-term debt, net of current portion	0	179,882
Deferred revenue, net of current portion, including of $0 and $21,205 from related parties as of September 30, 2022 and December 31, 2021, respectively	1,818	23,023
Lease liabilities, net of current portion	7,939	8,747
Deferred tax liabilities	2,092	2,539
Long-term liabilities held for sale	0	3,672
Total liabilities	116,713	252,508
Commitments and contingencies (Note 16)
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 208,150,021 shares and 206,739,874 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	0	0
Additional paid-in capital	1,996,104	2,022,701
Accumulated deficit	(1,846,391)	(1,915,556)
Accumulated other comprehensive (loss) income	(7,181)	203
Total shareholders' equity	142,532	107,348
Total liabilities and shareholders' equity	$ 259,245	$ 359,856

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Accounts receivable allowance for credit losses	$ 184,000	$ 184,000
Related party receivable, allowance for credit losses		1,509,000
Current liabilities
Deferred revenue, net of current portion, related party	$ 1,818,000	$ 23,023,000
Shareholders' equity
Common stock, no par value (in usd per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	208,150,021	206,739,874
Common stock, shares outstanding (in shares)	208,150,021	206,739,874
Related Parties, Aggregated
Current liabilities
Deferred revenue, net of current portion, related party	$ 0	$ 21,205,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Total revenues	$ 16,722	$ 3,333	$ 25,146	$ 10,583
Operating Expenses
Impairment of goodwill			482	0
Impairment of other noncurrent assets			638	543
Other Expense, Net
Equity in net income (loss) of affiliates			861	(3)
Loss from continuing operations before income taxes	(7,694)	(26,380)	(57,798)	(84,282)
Income (loss) from discontinued operations, net of income taxes	95,023	(3,445)	108,094	16,977
Net income (loss)	$ 87,379	$ (29,764)	$ 50,493	$ (67,132)
Net Loss per Share
Net loss from continuing operations per share, basic (in dollars per share)	$ (0.04)	$ (0.13)	$ (0.29)	$ (0.43)
Net loss from continuing operating per share, diluted (in dollars per share)	(0.04)	(0.13)	(0.29)	(0.43)
Net income (loss) from discontinued operations per share, diluted (in dollars per share)	0.48	(0.02)	0.54	0.09
Net income (loss) from discontinued operations per share, basic (in dollars per share)	0.48	(0.02)	0.54	0.09
Net income (loss) per share, basic (in dollars per share)	0.44	(0.15)	0.25	(0.34)
Net income (loss) per share, diluted (in dollars per share)	$ 0.44	$ (0.15)	$ 0.25	$ (0.34)
Weighted average shares outstanding, basic (in shares)	200,670,590	199,179,763	200,256,046	197,254,438
Weighted average shares outstanding, diluted (in shares)	200,670,590	199,179,763	200,256,046	197,254,438
Collaboration and licensing agreements
Revenues
Total revenues	$ 14,561	$ 22	$ 14,561	$ 389
Continuing Operations
Revenues
Total revenues	16,722	3,333	25,146	10,583
Operating Expenses
Research and development	12,622	12,434	36,377	35,755
Selling, general and administrative	10,137	10,977	36,496	40,197
Impairment of goodwill	0	0	482	0
Impairment of other noncurrent assets	0	0	638	543
Total operating expenses	24,336	24,863	79,075	80,659
Operating loss	(7,614)	(21,530)	(53,929)	(70,076)
Other Expense, Net
Interest expense	(2,036)	(4,765)	(6,137)	(13,902)
Interest income	56	48	131	129
Other income (expense), net	1,038	(133)	1,276	(430)
Total other expense, net	(942)	(4,850)	(4,730)	(14,203)
Equity in net income (loss) of affiliates	862	0	861	(3)
Loss from continuing operations before income taxes	(7,694)	(26,380)	(57,798)	(84,282)
Income tax benefit	50	61	197	173
Loss from continuing operations	(7,644)	(26,319)	(57,601)	(84,109)
Continuing Operations | Collaboration and licensing agreements
Revenues
Total revenues	14,561	22	14,561	389
Continuing Operations | Product revenues
Revenues
Total revenues	342	554	1,455	1,860
Operating Expenses
Cost of products and services	463	482	1,585	1,306
Continuing Operations | Service revenues
Revenues
Total revenues	1,750	2,632	8,896	7,935
Operating Expenses
Cost of products and services	1,114	970	3,497	2,858
Continuing Operations | Other
Revenues
Total revenues	$ 69	$ 125	$ 234	$ 399

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transaction [Line Items]
Total revenues	$ 16,722	$ 3,333	$ 25,146	$ 10,583
Continuing Operations
Related Party Transaction [Line Items]
Total revenues	16,722	3,333	25,146	10,583
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Total revenues	14,561	22	14,561	389
Collaboration and licensing agreements | Continuing Operations
Related Party Transaction [Line Items]
Total revenues	$ 14,561	$ 22	$ 14,561	$ 389

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 87,379	$ (29,764)	$ 50,493	$ (67,132)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	99	42	(905)	(43)
Loss on foreign currency translation adjustments	(2,724)	(1,068)	(6,479)	(2,439)
Comprehensive income (loss)	$ 84,754	$ (30,790)	$ 43,109	$ (69,614)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Balances (in shares) at Dec. 31, 2020			187,663,207
Balances at Dec. 31, 2020	$ 67,174		$ 0	$ 1,886,567		$ 3,997	$ (1,823,390)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	11,462			11,462
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)			1,750,521
Shares issued upon vesting of restricted stock units and for exercises of stock options	603			603
Shares issued as payment for services (in shares)			74,771
Shares issued as payment for services	577			577
Shares issued in public offering, net of issuance costs (in shares)			17,250,000
Shares issued in public offerings, net of issuance costs	121,045			121,045
Net income	(67,132)						(67,132)
Other comprehensive loss	(2,482)					(2,482)
Balances (in shares) at Sep. 30, 2021			206,738,499
Balances at Sep. 30, 2021	131,247		$ 0	2,020,254		1,515	(1,890,522)
Balances (in shares) at Dec. 31, 2020			187,663,207
Balances at Dec. 31, 2020	$ 67,174		$ 0	1,886,567		3,997	(1,823,390)
Increase (Decrease) in Stockholders' Equity
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Balances (in shares) at Dec. 31, 2021	206,739,874		206,739,874
Balances at Dec. 31, 2021	$ 107,348	$ (18,196)	$ 0	2,022,701	$ (36,868)	203	(1,915,556)	$ 18,672
Balances (in shares) at Jun. 30, 2021			206,580,928
Balances at Jun. 30, 2021	159,196		$ 0	2,017,413		2,541	(1,860,758)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	2,490			2,490
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)			157,571
Shares issued upon vesting of restricted stock units and for exercises of stock options	351			351
Net income	(29,764)						(29,764)
Other comprehensive loss	(1,026)					(1,026)
Balances (in shares) at Sep. 30, 2021			206,738,499
Balances at Sep. 30, 2021	$ 131,247		$ 0	2,020,254		1,515	(1,890,522)
Balances (in shares) at Dec. 31, 2021	206,739,874		206,739,874
Balances at Dec. 31, 2021	$ 107,348	$ (18,196)	$ 0	2,022,701	$ (36,868)	203	(1,915,556)	$ 18,672
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	7,996			7,996
Shares issued upon vesting of restricted stock units and for exercises of stock options (in shares)			354,089
Shares issued upon vesting of restricted stock units and for exercises of stock options	1			1
Shares issued for accrued compensation (in shares)			772,071
Shares issued for accrued compensation	1,698			1,698
Shares issued as payment for services (in shares)			283,987
Shares issued as payment for services	576			576
Net income	50,493						50,493
Other comprehensive loss	$ (7,384)					(7,384)
Balances (in shares) at Sep. 30, 2022	208,150,021		208,150,021
Balances at Sep. 30, 2022	$ 142,532		$ 0	1,996,104		(7,181)	(1,846,391)
Balances (in shares) at Jun. 30, 2022			208,150,021
Balances at Jun. 30, 2022	55,653		$ 0	1,993,979		(4,556)	(1,933,770)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	2,125			2,125
Net income	87,379						87,379
Other comprehensive loss	$ (2,625)					(2,625)
Balances (in shares) at Sep. 30, 2022	208,150,021		208,150,021
Balances at Sep. 30, 2022	$ 142,532		$ 0	$ 1,996,104		$ (7,181)	$ (1,846,391)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net income	$ 50,493	$ (67,132)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	9,044	10,442
Gain on disposals of assets, net	421	89
Impairment of goodwill	482	0
Impairment of other noncurrent assets	638	543
Gain on sale of discontinued operations	(94,702)	0
Gain on debt retirement	(1,285)	0
Amortization of premiums on investments, net	667	893
Equity in net (income) loss of affiliates	(861)	3
Stock-based compensation expense	7,996	11,462
Shares issued as payment for services	576	577
Provision for credit losses	944	1,219
Accretion of debt discount and amortization of deferred financing costs	934	8,641
Deferred income taxes	(162)	(180)
Noncash gain on termination of operating leases	0	(4,602)
Other noncash items	105	0
Receivables:
Trade	(2,446)	(5,285)
Related parties	54	(47)
Other	230	(610)
Inventory	2,408	1,422
Prepaid expenses and other	(1,305)	(388)
Other assets	(1)	282
Accounts payable	728	(678)
Accrued compensation and benefits	(578)	(304)
Other accrued liabilities	(479)	1,505
Deferred revenue	(23,343)	903
Lease liabilities	(79)	107
Related party payables	(78)	4
Other long-term liabilities	(50)	(50)
Net cash used in operating activities	(49,649)	(41,182)
Cash flows from investing activities
Purchases of investments	0	(174,221)
Sales and maturities of investments	56,967	82,000
Purchases of property, plant and equipment	(4,871)	(4,474)
Proceeds from sale of assets	594	2,537
Proceeds from sale of discontinued operations	162,306	0
Proceeds from repayment of notes receivable	0	3,689
Net cash provided by (used in) investing activities	214,996	(90,469)
Cash flows from financing activities
Proceeds from issuance of shares, net of issuance costs	0	121,045
Repurchase of Convertible Notes	(115,658)	0
Payments of long-term debt	(353)	(351)
Proceeds from stock option exercises	1	603
Net cash (used in) provided by financing activities	(116,010)	121,297
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(804)	264
Net increase (decrease) in cash, cash equivalents, and restricted cash	48,533	(10,090)
Cash, cash equivalents, and restricted cash
Beginning of period	43,343	52,250
End of period	91,876	42,160
Supplemental disclosure of cash flow information
Cash paid during the period for interest	8,187	7,116
Cash paid during the period for income taxes	0	4
Significant noncash activities
Accrued compensation paid in equity awards	1,698	0
Purchases of property and equipment included in accounts payable and other accrued liabilities	199	108
Proceeds from sale of assets included in accounts receivable	147	124
Cash, cash equivalents, and restricted cash
Cash and cash equivalents	9,067
Restricted cash	82,443
Cash and cash equivalents included in current assets held for sale	0
Restricted cash included in other assets	366
Cash, cash equivalents, and restricted cash	$ 91,876	$ 42,160

Organization

Organization	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with a focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen operates through the following subsidiaries: PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland. Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium. Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa. Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform ("MBP") assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and had substantially completed the wind down by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. With the exception of certain assets and obligations with which the Company had a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion. On August 18, 2022, Precigen completed the previously announced sale of 100% of the issued and outstanding membership interests in its wholly-owned subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), a provider of reproductive technologies, including services and products sold to cattle breeders and other producers. See Note 3 for further discussion. Trans Ova was formerly a separate reportable segment. Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company."

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2022 and results of operations and cash flows for the periods ended September 30, 2022 and 2021. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying condensed consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated. Liquidity and Going Concern During the nine months ended September 30, 2022, the Company incurred a loss from continuing operations of $57,601 and used $49,649 of cash in its operations, and as of September 30, 2022, had an accumulated deficit of $1,846,391. The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows from operations to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In addition, as of September 30, 2022, the Company had $153,770 in cash, cash equivalents, short-term investments, and restricted cash, and had no committed source of additional funding from either debt or equity financings, although the Company may, in its discretion, sell equity securities under the terms of the at-the-market sales agreement (See Note 13), subject to certain conditions and limitations. Given the Company’s current cash position and forecasted negative cash flows from operating activities for the foreseeable future, as well as convertible notes with a face value of $82,440 that are due on July 1, 2023 (See Note 11), management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to fund its operations on an ongoing basis is dependent upon the successful execution of management’s plans, which include raising additional capital in the near term. This additional capital could be raised through a combination of non-dilutive financings (including collaborations, strategic alliances, monetization of non-core assets, marketing, distribution or licensing arrangements), dilutive financings (including equity and/or debt financings) and, in the longer term, from revenue related to product sales, to the extent its product candidates receive marketing approval and can be commercialized. There can be no assurance that new financings or other transactions will be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, monetization of non-core assets or marketing, distribution or licensing arrangement may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, which may include research and development and clinical trials. This may have a material adverse effect on the Company’s business, financial condition, results of operations and ability to operate as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern. Risks and Uncertainties The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of therapeutic product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its therapeutic product candidates. In addition, COVID-19 has had and continues to have an extensive impact on the global health and economic environments. Furthermore, there is uncertainty regarding the duration and severity of the ongoing pandemic, and the Company could experience delays or other pandemic-related events that may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future. The Company is closely monitoring the impact of COVID-19 on all aspects of its businesses. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses. See Note 3 for further discussion of the impact of COVID-19 on MBP Titan. Equity Method Investments The Company accounts for its investments in each of its joint ventures ("JVs") using the equity method of accounting based upon relative ownership interest. See additional discussion related to certain of the Company's JVs in Note 4. Variable Interest Entities As of December 31, 2021 and through July 2022, the Company determined that its JVs were variable interest entities ("VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. As of December 31, 2021 and through July 2022, the Company had no risk of loss related to the identified VIEs. In July 2022, the Company obtained substantially all of the membership interests that were previously owned by others of these VIEs, and began consolidating those entities at the time of the acquisitions. The operations and financial position of those entities were not material as of and for the three and nine months ended September 30, 2022. See Note 4 and Note 16 for additional discussion. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive to loss from continuing operations and, therefore, basic and diluted net loss per share were the same for all periods presented. The following potentially dilutive securities as of September 30, 2022 and 2021, have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended as they would have been anti-dilutive: September 30, 2022 2021 Convertible debt 4,836,112 11,732,440 Options 15,317,186 12,249,109 Restricted stock units 697,815 468,481 Warrants 121,888 121,888 Total 20,973,001 24,571,918 Segment Information The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. The financial information regularly reviewed by the CODM and the operating segments, which were determined to be operating and reportable segments, are (i) Biopharmaceuticals and (ii) Exemplar. The Biopharmaceuticals reportable segment is primarily comprised of the Company's legal entities of PGEN Therapeutics and ActoBio. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Exemplar. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, business development, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, gain or loss on disposals of assets, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio. The Company's segment presentation excludes amounts related to the operations of Trans Ova and MBP Titan which are reported as discontinued operations (Note 3). See Note 18 for further discussion of the Company's segments. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06" ) . Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported long-term debt outstanding, net of current portion, of $18,196, a decrease to our additional paid-in capital of $36,868, and a corresponding cumulative-effect reduction to our opening accumulated deficit of $18,672. The adoption of ASU 2020-06 is expected to reduce non-cash interest expense related to existing convertible debt outstanding by approximately $11,800 for the year ending December 31, 2022, and did not have an impact on our consolidated cash flows. The use of the if-converted method did not have an impact on our overall earnings per share calculation. Recently Issued Accounting Pronouncements Not Yet Adopted There are no accounting standards which have not yet been adopted that are expected to have a significant impact on our financial statements and related disclosures.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations Where applicable, the notes to the accompanying condensed consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations based on the discontinued operations summarized below. Trans Ova As part of the Company's strategic shift to becoming a primarily healthcare company, as discussed in Note 1, on August 18, 2022, the Company completed the previously announced sale of 100% of the issued and outstanding membership interests in its wholly-owned subsidiary,Trans Ova, to Spring Bidco LLC, a Delaware limited liability company for $170,000 and up to $10,000 in cash earn-out payments contingent upon the performance of Trans Ova in 2022 and 2023 (the “Transaction”). The Company received $162,306 in proceeds, net of certain transaction costs, on August 18, 2022, after giving effect to the preliminary closing purchase price adjustments. The final working capital adjustment of approximately $1,000 is expected to be received in the fourth quarter of 2022. The Company elected to account for the contingent consideration arrangement as a gain contingency in accordance with ASC 450, Contingencies (Subtopic 450-30). Under this approach, the Company recognizes the contingent consideration receivable in earnings after the contingency is resolved. Accordingly, to determine the initial gain on the sale of Trans Ova, the Company did not include an amount related to the contingent consideration arrangement as part of the consideration received. In connection with the Transaction, the Company, as of September 30, 2022, holds a total of $82,443, in a segregated account to be used for certain permitted purposes, including resolution of the Company’s outstanding convertible notes as discussed further in Note 11. In addition, the Company is required to indemnify the Buyer for certain expenses incurred post close (related to covenants and certain additional specified liabilities including certain patent infringement lawsuits), if incurred, in amounts not to exceed $5,750, which was recorded as a reduction of the gain on divestiture in the three and nine months ended September 30, 2022, and is included in other accrued liabilities as of September 30, 2022. To date, the Company has not received an indemnification claim. The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale related to Trans Ova as of December 31, 2021, are as follows: December 31, Assets Cash and cash equivalents $ 6,497 Trade receivables, net 19,491 Inventory 12,935 Other current assets 1,265 Property, plant and equipment, net 25,716 Intangible assets, net 1,824 Goodwill 16,594 Right-of-use assets 910 Other noncurrent assets 252 Total assets held for sale $ 85,484 Liabilities Accounts payable $ 2,293 Accrued compensation and benefits 3,367 Other accrued liabilities 3,778 Deferred revenue 2,952 Current portion of long-term debt 350 Other current liabilities 111 Long-term debt, net of current portion 2,867 Other long-term liabilities 805 Total liabilities held for sale $ 16,523 The following table presents the financial results of discontinued operations related to Trans Ova for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product revenues $ 4,322 $ 6,743 $ 21,494 $ 20,153 Service revenues 7,880 11,485 49,657 48,916 Total revenues 12,202 18,228 71,151 69,069 Cost of products 4,163 7,010 18,634 17,895 Cost of services 4,352 6,988 22,701 21,400 Research and development 481 486 2,348 1,367 Selling, general and administrative 3,204 7,683 15,215 17,162 Total operating expenses 12,200 22,167 58,898 57,824 Operating income (loss) 2 (3,939) 12,253 11,245 Other income, net 319 434 1,139 1,133 Gain on divestiture 94,702 — 94,702 — Income (loss) before income taxes 95,023 (3,505) 108,094 12,378 Income tax (expense) benefit — — — — Income (loss) from discontinued operations $ 95,023 $ (3,505) $ 108,094 $ 12,378 The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to Trans Ova that are included in the accompanying condensed consolidated statements of cash flows: Nine Months Ended 2022 2021 Adjustments to reconcile net income to net cash used in operating activities Depreciation and amortization $ 3,574 $ 4,268 Loss on disposal of assets 421 547 Stock-based compensation expense 9 272 Provision for credit losses 944 1,035 Cash flows from investing activities Purchases of property, plant and equipment (3,529) (2,731) Proceeds from sale of assets 594 1,425 MBP Titan As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially completed by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. This discontinuation of operations represented the continuation of a strategic shift to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges that the Company commenced in 2020. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are presented as discontinued operations in the accompanying condensed consolidated financial statements for all periods. The January 2021 sale of property and equipment resulted in a gain on disposal of assets of $464, which is included in income from discontinued operations in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2021. In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility that were originally due to expire in July 2025. This lease termination resulted in a gain of $4,602, which is also included in income from discontinued operations in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2021. After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), and Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), including the associated deferred revenue remaining under each collaboration agreement which was recognized as revenue in the third quarter of 2022 upon acquiring control of these entities (See Notes 2, 4, 5 and 16), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying condensed consolidated financial statements for all periods presented as a result of the Company's continuing involvement. There were no discontinued operations related to MBP Titan for the three and nine months ended September 30, 2022. The following table presents the financial results of discontinued operations related to MBP Titan for the three and nine months ended September 30, 2021: Three Months Ended Nine Months Ended 2021 2021 Operating gain 60 4,599 Operating gain 60 4,599 Gain from discontinued operations $ 60 $ 4,599 The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan for the nine months ended September 30, 2021 that are included in the accompanying condensed consolidated statements of cash flows. Nine Months Ended 2021 Adjustments to reconcile net loss to net cash used in operating activities Gain on disposals of assets $ (464) Noncash gain on termination of leases (4,602) Cash flows from investing activities Proceeds from sales of assets 1,083

Investments in Joint Ventures

Investments in Joint Ventures	9 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, a JV formed to optimize and scale-up the Company's MBP technology for the production of certain fuels and lubricants. The Company also entered into an exclusive channel collaboration ("ECC") with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Prior to Precigen’s purchase of certain membership interests from the IEP Investors in the third quarter of 2022 as discussed below and in Notes 3 and 16, two members of the Intrexon Energy Partners Board were designated by the Company and three members were designated by a majority of the IEP Investors. Upon accumulating 87.5% of the membership interests owned by the IEP Investors in the third quarter of 2022, the Company now has the right to designate all members of the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(428) as of December 31, 2021, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners. See Notes 3 and 16 for additional discussion regarding the Company's investment in Intrexon Energy Partners. Intrexon Energy Partners II In 2015, the Company and certain investors (the "IEPII Investors"), entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, a JV formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. Prior to Precigen’s purchase of the membership interests from the IEPII Investors in the third quarter of 2022, one member of the Intrexon Energy Partners II Board was designated by the Company and four members were designated by a majority of the IEPII Investors. Upon acquisition of all of the membership interests owned by the IEPII Investors in the third quarter of 2022 (the Company purchased the remaining 2.9% membership units in the fourth quarter of 2022), the Company now has the right to designate all members of the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(435) as of December 31, 2021, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II. See Notes 3 and 16 for additional discussion regarding the Company's investment in Intrexon Energy Partners II. Acquisition of Membership Interests in Intrexon Energy Partners and Intrexon Energy Partners II As discussed in Note 16, under the Arbitration Matter (as defined in Note 16) the Company acquired certain membership interests in both Intrexon Energy Partners and Intrexon Energy Partners II in the third quarter of 2022 for an aggregate amount of approximately $7,000. The Company recorded the $7,000 payment as a reduction of the revenue that was recognized in the third quarter of 2022 (from deferred revenue – see Note 5) upon the Company obtaining control of Intrexon Energy Partners and Intrexon Energy Partners II. The fair value of the net assets of Intrexon Energy Partners and Intrexon Energy Partners II at the acquisition date is deemed to be substantially $0.

Collaboration and Licensing Rev

Collaboration and Licensing Revenue	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Revenue	Collaboration and Licensing RevenueHistorically, the Company has derived collaboration and licensing revenue through agreements with counterparties for the development and commercialization of products enabled by the Company's technology platforms. These collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. The Company recognizes the reimbursement payments received for research and development efforts in the period when the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services, and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if any milestones will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC Topic 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. Intrexon Energy Partners and Intrexon Energy Partners II Collaborations In July 2022, the Company obtained control of the Board of Managers of each of Intrexon Energy Partners and Intrexon Energy Partners II (as discussed in Notes 3, 4, and 16). Based on its assessment of the status of each collaboration, the Company determined that there was a substantial likelihood that no further performance obligations would occur under the respective collaboration agreements. Accordingly, the Company recognized the remaining balance of deferred revenue associated with Intrexon Energy Partners and Intrexon Energy Partners II, less the amounts paid to acquire the membership interests of the investors for an aggregate amount of approximately $7,000. The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2022 and 2021. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Intrexon Energy Partners, LLC $ 3,768 — $ 3,768 $ — Intrexon Energy Partners II, LLC 10,793 — 10,793 — Castle Creek Biosciences, Inc. — 18 — 371 Other — 4 — 18 Total (1) $ 14,561 $ 22 $ 14,561 $ 389 (1) Collaboration and licensing revenues recognized are associated with upfront and milestone payments which were previously deferred. Excluding the agreements with Intrexon Energy Partners and Intrexon Energy Partners II, there have been no significant changes to the agreements with our collaborators and licensees in the three and nine months ended September 30, 2022. Deferred Revenue Deferred revenue primarily consists of upfront and milestone consideration received for the Company's collaboration and licensing agreements. Revenue is recognized as services are performed. The arrangements classified as long-term (of which $0 and $21,205 was related to agreements with Intrexon Energy Partners and Intrexon Energy Partners II as of September 30, 2022 and December 31, 2021, respectively ) are not active while the respective counterparties evaluate the status of the project and its desired future development activities since the Company cannot reasonably estimate the amount of service to be performed over the next year. Deferred revenue consisted of the following: September 30, December 31, Collaboration and licensing agreements $ 1,818 $ 23,023 Prepaid product and service revenues 52 1,277 Other 24 213 Total $ 1,894 $ 24,513 Current portion of deferred revenue $ 76 $ 1,490 Long-term portion of deferred revenue 1,818 23,023 Total $ 1,894 $ 24,513

Short-term and Long-term Invest

Short-term and Long-term Investments	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Short-term and Long-term Investments	Short-term and Long-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of September 30, 2022: Amortized Gross Gross Aggregate U.S. government debt securities $ 63,400 $ — $ (1,236) $ 62,164 Certificates of deposit 96 — — 96 Total $ 63,496 $ — $ (1,236) $ 62,260 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021: Amortized Gross Gross Aggregate U.S. government debt securities $ 121,036 $ — $ (331) $ 120,705 Certificates of deposit 97 — — 97 Total $ 121,133 $ — $ (331) $ 120,802 The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2022 was: Due within one year $ 62,260 After one year through two years — Total $ 62,260 Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amount of cash and cash equivalents, restricted cash, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of September 30, 2022: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs September 30, Assets U.S. government debt securities $ — $ 62,164 $ — $ 62,164 Certificates of deposit — 96 — 96 Total $ — $ 62,260 $ — $ 62,260 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 120,705 $ — $ 120,705 Certificates of deposit — 97 — 97 Total $ — $ 120,802 $ — $ 120,802 The method used to estimate the fair value of the Level 2 short-term and long-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Liabilities The fair value of the 3.50% convertible senior notes due 2023 (the "Convertible Notes") (Note 11) was approximately $81,000 and $160,000 as of September 30, 2022 and December 31, 2021, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying condensed consolidated balance sheets at amortized cost, which was $82,069 and $179,882 as of September 30, 2022 and December 31, 2021, respectively (see Note 2 regarding adoption of ASU 2020-06 on January 1, 2022).

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: September 30, December 31, Supplies, embryos and other production materials $ 19 $ 23 Livestock 200 303 Total inventory $ 219 $ 326

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment consist of the following: September 30, December 31, Land and land improvements $ 164 $ 164 Buildings and building improvements 2,592 2,592 Furniture and fixtures 449 434 Equipment 17,694 16,812 Leasehold improvements 3,495 3,366 Breeding stock 117 36 Computer hardware and software 4,518 4,823 Construction and other assets in progress 1,240 1,829 30,269 30,056 Less: Accumulated depreciation and amortization (22,658) (21,457) Property, plant and equipment, net $ 7,611 $ 8,599 Depreciation expense was $564 and $735 for the three months ended September 30, 2022 and 2021, respectively, and $1,833 and $2,184 for the nine months ended September 30, 2022 and 2021, respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows: Balance at December 31, 2021 $ 37,554 Impairment (482) Foreign currency translation adjustments (359) Balance at September 30, 2022 $ 36,713 The Company recorded $482 of goodwill impairment related to the total goodwill assigned to one reporting unit within the biopharmaceutical segment during the first quarter of 2022. The Company had $14,483 and $14,001 of cumulative impairment losses as of September 30, 2022 and December 31, 2021, respectively. Intangible assets consist of the following as of September 30, 2022: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 75,129 $ (32,713) $ 42,416 Customer relationships 1,600 (1,600) — Trademarks 200 (200) — Total $ 76,929 $ (34,513) $ 42,416 Intangible assets consist of the following as of December 31, 2021: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 85,173 $ (32,882) $ 52,291 Customer relationships 1,600 (1,600) — Trademarks 200 (200) — Total $ 86,973 $ (34,682) $ 52,291 Amortization expense was $1,151 and $1,315 for the three months ended September 30, 2022 and 2021, respectively, and $3,637 and $3,990 for the nine months ended September 30, 2022 and 2021, respectively.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Lines of Credit and Long-Term Debt	Lines of Credit and Long-Term Debt Lines of Credit Exemplar has a $700 revolving line of credit with American State Bank that matured on October 31, 2022, and is currently being renegotiated with the bank. As of September 30, 2022, the line of credit bore interest at a stated rate of 4.00% per annum. As of September 30, 2022 and December 31, 2021, there was no outstanding balance. Long-Term Debt Long-term debt consists of the following: September 30, December 31, Convertible debt (1) $ 82,069 $ 179,882 Other — 52 Long-term debt 82,069 179,934 Less current portion 82,069 52 Long-term debt, less current portion $ — $ 179,882 (1) See Note 2 regarding adoption of ASU 2020-06 as of January 1, 2022. Convertible Debt Precigen Convertible Notes In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042. The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the three or nine months ended September 30, 2022. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. The Convertible Notes do not allow Precigen to call the debt prior to the maturity date. If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount. As described in Note 2, the Company adopted ASU 2020-06 on January 1, 2022. Pursuant to ASU 2020-06, the equity components of the Convertible Notes separated from the debt components as required under the cash conversion model is required to be recombined into the Convertible Notes as a single instrument upon the adoption of ASU 2020-06. The Convertible Notes shall be accounted for as if the conversion option had not been separated. As the Company elected the modified retrospective approach, the difference between the accounting under the cash conversion model and new model after the adoption of ASU 2020-06 (i.e., the single debt instrument with no separation) was recorded as an adjustment on the adoption date (i.e., January 1, 2022) through accumulated deficit. Tax accounting consequences of the adoption also required the reversal of the previously reported deferred tax benefit on the date of adoption. Adoption of ASU 2020-06 resulted in an increase to long-term debt outstanding, net of current portion, of $18,196, a decrease to additional paid-in capital of $36,868, and a decrease to accumulated deficit of $18,672. Interest expense recognized on the convertible notes in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. As discussed in Note 3, in connection with the sale of Trans Ova, the Company transferred a total of $200,000 into a segregated account to be used for certain permitted purposes, including resolution of the Company's outstanding Convertibles Notes. During and subsequent to the quarter ended September 30, 2022, the Company executed open market purchases of a portion of the outstanding Convertible Notes. During the three months ended September 30, 2022, the Company successfully retired $117,560 of principal balance from these purchases and recorded a gain on extinguishment of debt of approximately $853, which was recorded within Other income (expense), net, within the condensed consolidated statements of operations. As of September 30, 2022, $82,443 remained in the segregated account noted above for permitted purposes including the resolution of the Company's outstanding Convertible Notes. Additionally, in October and November 2022, the Company completed additional purchases, retiring an additional principal balance totaling $26,400. As of September 30, 2022, the outstanding principal balance on the Convertible Notes was $82,440 and their carrying value was $82,069. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 4.25%. As of September 30, 2022, the unamortized debt discount and debt issuance costs related to the Convertible Notes totaled $371. The components of interest expense related to the Convertible Notes were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cash interest expense $ 1,697 $ 1,750 $ 5,197 $ 5,250 Non-cash interest expense 338 3,011 934 8,641 Total interest expense $ 2,035 $ 4,761 $ 6,131 $ 13,891 Accrued interest of $721 is included in other accrued liabilities on the accompanying condensed consolidated balance sheet as of September 30, 2022. Future Maturities The Convertible Notes mature on July 1, 2023.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. The Company has U.S. taxable income, prior to utilization of net operating losses, of approximately $44,300 for the three months ended September 30, 2022, and had U.S taxable loss of approximately $24,700 for the three months ended September 30, 2021. The Company has U.S. taxable income, prior to utilization of net operating losses, of $38,000 for the nine months ended September 30, 2022 and had U.S. taxable losses of $82,200 for the nine months ended September 30, 2021. The following table presents the components of income tax benefit from continuing operations. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Current foreign income tax expense (benefit) from continuing operations $ — $ — $ (35) $ 7 Deferred income tax benefit from continuing operations (50) (61) (162) (180) Total income tax benefit from continuing operations $ (50) $ (61) $ (197) $ (173) The Company's net deferred tax assets are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. As of September 30, 2022, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $818,000 available to offset future taxable income, including approximately $603,000 generated after 2017, U.S. capital loss carryforwards of approximately $212,500, and federal and state research and development tax credits of approximately $11,700, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. Net operating loss carryforwards generated prior to 2018 have begun to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. As of September 30, 2022, the Company's foreign subsidiaries have foreign loss carryforwards of approximately $64,200, most of which do not expire.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Issuances of Precigen Common Stock In January 2021, the Company closed a public offering of 17,250,000 shares of its common stock, resulting in net proceeds of $121,045, after deducting underwriting discounts and of capitalized offering expenses. See Note 11 for discussion regarding conversion features of the convertible notes. Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 11), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within five The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement. At-the-Market Sales Agreement On August 9, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may issue and sell from time to time shares of the Company’s common stock, no par value per share (the “Shares”), through the Agent. The offering and sale of up to $100,000 of the Shares has been registered under the Securities Act of 1933. The Company has no obligation to sell any of the Shares under the Sales Agreement, and may at any time suspend or terminate the offering of its common stock pursuant to the Sales Agreement upon notice and subject to other conditions. The Company intends to use the proceeds of any sales to fund the development of clinical and preclinical product candidates and for working capital and other general corporate purposes. No Shares were sold in connection with the Sales Agreement during the three months ended September 30, 2022. Components of Accumulated Other Comprehensive (Loss) Income The components of accumulated other comprehensive (loss) income are as follows: September 30, December 31, Unrealized loss on investments $ (1,236) $ (331) Income (loss) on foreign currency translation adjustments (5,945) 534 Total accumulated other comprehensive (loss) income $ (7,181) $ 203

Share-Based Payments

Share-Based Payments	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Payments	Share-Based Payments The Company measures the fair value of stock options and restricted stock units ("RSUs") issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the condensed consolidated statements of operations are presented below: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of products $ 7 $ 8 $ 22 $ 23 Cost of services 15 25 63 103 Research and development 524 549 1,658 2,159 Selling, general and administrative 1,638 1,840 6,244 8,905 Discontinued operations (59) 68 9 272 Total $ 2,125 $ 2,490 $ 7,996 $ 11,462 Precigen Stock Option Plans In April 2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share-based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of September 30, 2022, there were 14,843 stock options outstanding under the 2008 Plan. Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of September 30, 2022, there were 37,000,000 shares authorized for issuance under the 2013 Plan, of which 13,404,135 stock options and 82,055 RSUs were outstanding and 12,833,550 shares were available for grant. In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of September 30, 2022, there were 12,000,000 shares authorized for issuance under the 2019 Plan, of which 1,898,208 stock options and 615,760 RSUs were outstanding and 7,243,025 shares were available for grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2021 12,260,187 $ 14.06 6.79 Granted 4,322,890 2.23 Exercised (375) 2.28 Forfeited (544,928) 5.21 Expired (720,588) 23.44 Balances at September 30, 2022 15,317,186 10.60 7.28 Exercisable at September 30, 2022 8,715,518 13.77 5.84 RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2021 468,481 $ 8.47 0.33 Granted 1,387,831 2.12 Vested (1,125,785) 4.29 Forfeited (32,712) 7.26 Balances at September 30, 2022 697,815 2.66 0.38 Precigen currently uses authorized and unissued shares to satisfy share award exercises. The Company's Executive Chairman ("Executive Chairman"), who previously served as an employee and executive officer until September 24, 2020, received a base salary of $200 per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale. In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman consisting of (i) an annual retainer of $100 payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully vested stock options having a grant date fair value of $250; and (iii) an annual grant of RSUs having a grant date fair value of $250 vesting over one year. The new compensation arrangement began in calendar year 2021 and was prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. Expense associated with the arrangements above is included in selling, general, and administrative expenses in the Company's condensed consolidated statements of operations and totaled $63 and $76 for the three months ended September 30, 2022 and 2021, respectively, and $558 and $585 for the nine months ended September 30, 2022 and 2021, respectively.

Operating Leases

Operating Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Operating Leases	Operating LeasesThe Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of one The components of lease costs were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Operating lease costs $ 600 $ 770 $ 1,840 $ 2,290 Short-term lease costs 53 48 155 141 Variable lease costs 84 185 308 623 Lease costs $ 737 $ 1,003 $ 2,303 $ 3,054 As of September 30, 2022, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2022 $ 449 2023 2,084 2024 2,165 2025 2,129 2026 1,637 2027 1,246 Thereafter 3,109 Total 12,819 Present value adjustment (3,839) Total $ 8,980 Current portion of operating lease liabilities $ 1,041 Long-term portion of operating lease liabilities 7,939 Total $ 8,980 Other information related to operating leases in continuing operations was as follows: September 30, December 31, Weighted average remaining lease term (years) 6.15 6.72 Weighted average discount rate 11.06 % 10.94 % Nine Months Ended 2022 2021 Supplemental disclosure of cash flow information Cash paid for operating lease liabilities $ 1,877 $ 2,610 Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases) 466 4,868

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies In September 2020, the Company reached a final settlement with the Securities and Exchange Commission ("SEC") with respect to an investigation concerning the Company's disclosures regarding its MBP program in the first three quarters of 2017. In October 2020, several shareholder class action lawsuits were filed in the United States District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiffs' claims challenged disclosures about the MBP program from May 10, 2017 to March 1, 2019. In March 2021, the court granted an order consolidating the claims and, in April 2021, appointed a lead plaintiff and lead counsel in the case, captioned In re Precigen Securities Litigation, Case No. 5:20-cv-06936- BLF (N.D. Cal.). In May 2021, the lead plaintiff filed an amended complaint. The defendants moved to dismiss that complaint. In September 2021, the court issued an order mooting the defendants' motion to dismiss in light of the lead plaintiff's stated intent to file a second amended complaint in response to the motion to dismiss. On September 27, 2021, the lead plaintiff filed a second amended complaint, which the defendants moved to dismiss. On May 31, 2022, the court granted the motion, dismissing the second amended complaint with leave to amend. On August 1, 2022, the lead plaintiff filed a third amended complaint. On August 2, 2022, the Court granted the parties’ stipulated request to vacate all case deadlines to permit the parties to conduct a private mediation session to explore potential resolution of the action. In the event that litigation resumes, the defendants intend to move to dismiss the third amended complaint. In December 2020, a derivative shareholder action, captioned Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al , was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. asserting similar claims under state law against Precigen's current directors and certain officers. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The case was stayed by an order entered on June 14, 2021. On September 24, 2021, an individual shareholder filed a lawsuit in the Circuit Court for Henrico County styled Kent v. Precigen, Inc. , Case CL21-6349. The Kent action demands inspection of certain books and records of the Company pursuant to Virginia statutory and common law. On April 1, 2022, the court denied the demurrer and referred the matter to a hearing on the merits. The Company is evaluating how best to proceed. The Company intends to defend the lawsuits vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits. The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including the IEP Investors and the IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, in 2019, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding. On December 29, 2021, the Company received a letter from a group of investors in each of Intrexon Energy Partners and Intrexon Energy Partners II, referring certain issues to arbitration pursuant to the arbitration provisions of the Amended and Restated Limited Liability Company Agreements of Intrexon Energy Partners and Intrexon Energy Partners II (the “Arbitration Matters”). In July 2022, the arbitration panel ruled on the Arbitration Matters, and adopted the Company’s proposed terms with respect to each of the Arbitration Matters and, pursuant to that ruling, the Company acquired the membership interests of the investors for an aggregate amount of approximately $7,000 in cash. See Notes 4 and 5 for additional discussion of the accounting for the acquisition of the membership interests. In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters may result in adverse judgments, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company’s business or operations. Moreover, such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2022, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns 100% of the equity interests of Third Security. The Company had an agreement with Third Security under which the Company reimbursed Third Security for certain tax-related services performed by Third Security as requested by the Company. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf. The agreement with Third Security expired on December 31, 2021. As the Company evaluates its alternatives, it continues to utilize these services on a limited basis under the terms of the original agreement. The total expenses incurred by the Company under these arrangements were $43 for the three months ended September 30, 2021, and $25 and $89 for the nine months ended September 30, 2022 and 2021, respectively. See also Note 14 regarding compensation arrangements between the Company and its Executive Chairman. Through November 2021, the Company also subleased certain administrative offices to Third Security. The significant terms of the lease mirrored the terms of the Company's lease with the landlord, and the Company recorded sublease income of $21 for the three months ended September 30, 2021, and $61 for the nine months ended September 30, 2021. See Note 13 regarding additional transactions with affiliates of Third Security.

Segments

Segments	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segments	Segments The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA as a basis. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net gain (loss) of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates, but includes proceeds from the sale of assets in the period sold. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the operations of Trans Ova and MBP Titan which are reported as discontinued operations (Note 3). For the three and nine months ended September 30, 2022, the Company's reportable segments were (i) Biopharmaceuticals and (ii) Exemplar. These identified reportable segments met the quantitative thresholds to be reported separately for the nine months ended September 30, 2022. See Note 2 for a description of the Biopharmaceuticals segment. See Note 1 for a description of the Exemplar segment. Segment Adjusted EBITDA by reportable segment was as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Biopharmaceuticals $ (12,417) $ (12,661) $ (35,286) $ (34,055) Exemplar 346 1,617 4,699 5,312 Segment Adjusted EBITDA for reportable segments $ (12,071) $ (11,044) $ (30,587) $ (28,743) The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Segment Adjusted EBITDA for reportable segments $ (12,071) $ (11,044) $ (30,587) $ (28,743) Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates 641 1,138 1,309 1,673 Add recognition of previously deferred revenue associated with upfront and milestone payments 14,561 1,163 16,007 1,849 Other expenses: Interest expense (2,036) (4,765) (6,137) (13,902) Depreciation and amortization (1,717) (2,029) (5,470) (6,174) Gain on disposals of assets — (13) — (6) Impairment losses — — (1,120) (543) Stock-based compensation expense (2,184) (2,422) (7,987) (11,767) Adjustment related to accrued bonuses paid in equity awards — — 1,698 — Equity in net gain (loss) of affiliates 862 — 861 (3) Other — (5) (105) (19) Unallocated corporate costs (5,744) (7,166) (24,718) (24,835) Eliminations (6) (1,237) (1,549) (1,812) Consolidated net loss from continuing operations before income taxes $ (7,694) $ (26,380) $ (57,798) $ (84,282) Revenues by reportable segment were as follows: Three Months Ended September 30, 2022 Biopharmaceuticals Exemplar Total Revenues from external customers $ 14,624 $ 2,098 $ 16,722 Intersegment revenues — — — Total segment revenues $ 14,624 $ 2,098 $ 16,722 Three Months Ended September 30, 2021 Biopharmaceuticals Exemplar Total Revenues from external customers $ 129 $ 3,204 $ 3,333 Intersegment revenues 1,141 — 1,141 Total segment revenues $ 1,270 $ 3,204 $ 4,474 Nine Months Ended September 30, 2022 Biopharmaceuticals Exemplar Total Revenues from external customers $ 14,778 $ 10,368 $ 25,146 Intersegment revenues 1,446 — 1,446 Total segment revenues $ 16,224 $ 10,368 $ 26,592 Nine Months Ended September 30, 2021 Biopharmaceuticals Exemplar Total Revenues from external customers $ 723 $ 9,860 $ 10,583 Intersegment revenues 1,469 — 1,469 Total segment revenues $ 2,192 $ 9,860 $ 12,052 The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Total segment revenues from reportable segments $ 16,722 $ 4,474 $ 26,592 $ 12,052 Elimination of intersegment revenues — (1,141) (1,446) (1,469) Total consolidated revenues $ 16,722 $ 3,333 $ 25,146 $ 10,583 For the three months ended September 30, 2022 and 2021, 41.1% and 75.6%, respectively, of total consolidated revenue was attributable to one and two customers, respectively, in the Exemplar segment. For the nine months ended September 30, 2022 and 2021, 62.4% and 60.7%, respectively, of total consolidated revenue was attributable to one customer in the Exemplar segment. As of September 30, 2022 and December 31, 2021, the Company had $3,122 and $4,463, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $63 and $93 for the three months ended September 30, 2022 and 2021, respectively, and $217 and $296 for the nine months ended September 30, 2022 and 2021, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2022 and results of operations and cash flows for the periods ended September 30, 2022 and 2021. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with
Consolidation	The accompanying condensed consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated. Liquidity and Going Concern During the nine months ended September 30, 2022, the Company incurred a loss from continuing operations of $57,601 and used $49,649 of cash in its operations, and as of September 30, 2022, had an accumulated deficit of $1,846,391. The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows from operations to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In addition, as of September 30, 2022, the Company had $153,770 in cash, cash equivalents, short-term investments, and restricted cash, and had no committed source of additional funding from either debt or equity financings, although the Company may, in its discretion, sell equity securities under the terms of the at-the-market sales agreement (See Note 13), subject to certain conditions and limitations. Given the Company’s current cash position and forecasted negative cash flows from operating activities for the foreseeable future, as well as convertible notes with a face value of $82,440 that are due on July 1, 2023 (See Note 11), management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to fund its operations on an ongoing basis is dependent upon the successful execution of management’s plans, which include raising additional capital in the near term. This additional capital could be raised through a combination of non-dilutive financings (including collaborations, strategic alliances, monetization of non-core assets, marketing, distribution or licensing arrangements), dilutive financings (including equity and/or debt financings) and, in the longer term, from revenue related to product sales, to the extent its product candidates receive marketing approval and can be commercialized. There can be no assurance that new financings or other transactions will be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, monetization of non-core assets or marketing, distribution or licensing arrangement may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, which may include research and development and clinical trials. This may have a material adverse effect on the Company’s business, financial condition, results of operations and ability to operate as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.
Equity Method Investments	Equity Method InvestmentsThe Company accounts for its investments in each of its joint ventures ("JVs") using the equity method of accounting based upon relative ownership interest.
Variable Interest Entities	Variable Interest EntitiesAs of December 31, 2021 and through July 2022, the Company determined that its JVs were variable interest entities ("VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs.
Net Loss Per Share	Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive to loss from continuing operations and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information	Segment Information The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. The financial information regularly reviewed by the CODM and the operating segments, which were determined to be operating and reportable segments, are (i) Biopharmaceuticals and (ii) Exemplar. The Biopharmaceuticals reportable segment is primarily comprised of the Company's legal entities of PGEN Therapeutics and ActoBio. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Exemplar. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, business development, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, gain or loss on disposals of assets, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio. The Company's segment presentation excludes amounts related to the operations of Trans Ova and MBP Titan which are reported as discontinued operations (Note 3). See Note 18 for further discussion of the Company's segments.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06" ) . Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported long-term debt outstanding, net of current portion, of $18,196, a decrease to our additional paid-in capital of $36,868, and a corresponding cumulative-effect reduction to our opening accumulated deficit of $18,672. The adoption of ASU 2020-06 is expected to reduce non-cash interest expense related to existing convertible debt outstanding by approximately $11,800 for the year ending December 31, 2022, and did not have an impact on our consolidated cash flows. The use of the if-converted method did not have an impact on our overall earnings per share calculation. Recently Issued Accounting Pronouncements Not Yet Adopted There are no accounting standards which have not yet been adopted that are expected to have a significant impact on our financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share	The following potentially dilutive securities as of September 30, 2022 and 2021, have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended as they would have been anti-dilutive: September 30, 2022 2021 Convertible debt 4,836,112 11,732,440 Options 15,317,186 12,249,109 Restricted stock units 697,815 468,481 Warrants 121,888 121,888 Total 20,973,001 24,571,918

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale related to Trans Ova as of December 31, 2021, are as follows: December 31, Assets Cash and cash equivalents $ 6,497 Trade receivables, net 19,491 Inventory 12,935 Other current assets 1,265 Property, plant and equipment, net 25,716 Intangible assets, net 1,824 Goodwill 16,594 Right-of-use assets 910 Other noncurrent assets 252 Total assets held for sale $ 85,484 Liabilities Accounts payable $ 2,293 Accrued compensation and benefits 3,367 Other accrued liabilities 3,778 Deferred revenue 2,952 Current portion of long-term debt 350 Other current liabilities 111 Long-term debt, net of current portion 2,867 Other long-term liabilities 805 Total liabilities held for sale $ 16,523 The following table presents the financial results of discontinued operations related to Trans Ova for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product revenues $ 4,322 $ 6,743 $ 21,494 $ 20,153 Service revenues 7,880 11,485 49,657 48,916 Total revenues 12,202 18,228 71,151 69,069 Cost of products 4,163 7,010 18,634 17,895 Cost of services 4,352 6,988 22,701 21,400 Research and development 481 486 2,348 1,367 Selling, general and administrative 3,204 7,683 15,215 17,162 Total operating expenses 12,200 22,167 58,898 57,824 Operating income (loss) 2 (3,939) 12,253 11,245 Other income, net 319 434 1,139 1,133 Gain on divestiture 94,702 — 94,702 — Income (loss) before income taxes 95,023 (3,505) 108,094 12,378 Income tax (expense) benefit — — — — Income (loss) from discontinued operations $ 95,023 $ (3,505) $ 108,094 $ 12,378 The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to Trans Ova that are included in the accompanying condensed consolidated statements of cash flows: Nine Months Ended 2022 2021 Adjustments to reconcile net income to net cash used in operating activities Depreciation and amortization $ 3,574 $ 4,268 Loss on disposal of assets 421 547 Stock-based compensation expense 9 272 Provision for credit losses 944 1,035 Cash flows from investing activities Purchases of property, plant and equipment (3,529) (2,731) Proceeds from sale of assets 594 1,425 Three Months Ended Nine Months Ended 2021 2021 Operating gain 60 4,599 Operating gain 60 4,599 Gain from discontinued operations $ 60 $ 4,599 The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan for the nine months ended September 30, 2021 that are included in the accompanying condensed consolidated statements of cash flows. Nine Months Ended 2021 Adjustments to reconcile net loss to net cash used in operating activities Gain on disposals of assets $ (464) Noncash gain on termination of leases (4,602) Cash flows from investing activities Proceeds from sales of assets 1,083

Collaboration and Licensing R_2

Collaboration and Licensing Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summarized Collaboration and Licensing Revenues	The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2022 and 2021. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Intrexon Energy Partners, LLC $ 3,768 — $ 3,768 $ — Intrexon Energy Partners II, LLC 10,793 — 10,793 — Castle Creek Biosciences, Inc. — 18 — 371 Other — 4 — 18 Total (1) $ 14,561 $ 22 $ 14,561 $ 389 (1) Collaboration and licensing revenues recognized are associated with upfront and milestone payments which were previously deferred.
Summary of Deferred Revenue	Deferred revenue consisted of the following: September 30, December 31, Collaboration and licensing agreements $ 1,818 $ 23,023 Prepaid product and service revenues 52 1,277 Other 24 213 Total $ 1,894 $ 24,513 Current portion of deferred revenue $ 76 $ 1,490 Long-term portion of deferred revenue 1,818 23,023 Total $ 1,894 $ 24,513
Summary of Deferred Revenue by Collaborator

Short-term and Long-term Inve_2

Short-term and Long-term Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments	The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of September 30, 2022: Amortized Gross Gross Aggregate U.S. government debt securities $ 63,400 $ — $ (1,236) $ 62,164 Certificates of deposit 96 — — 96 Total $ 63,496 $ — $ (1,236) $ 62,260 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021: Amortized Gross Gross Aggregate U.S. government debt securities $ 121,036 $ — $ (331) $ 120,705 Certificates of deposit 97 — — 97 Total $ 121,133 $ — $ (331) $ 120,802
Contractual Obligation, Fiscal Year Maturity	The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2022 was: Due within one year $ 62,260 After one year through two years — Total $ 62,260

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of September 30, 2022: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs September 30, Assets U.S. government debt securities $ — $ 62,164 $ — $ 62,164 Certificates of deposit — 96 — 96 Total $ — $ 62,260 $ — $ 62,260 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 120,705 $ — $ 120,705 Certificates of deposit — 97 — 97 Total $ — $ 120,802 $ — $ 120,802

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: September 30, December 31, Supplies, embryos and other production materials $ 19 $ 23 Livestock 200 303 Total inventory $ 219 $ 326

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following: September 30, December 31, Land and land improvements $ 164 $ 164 Buildings and building improvements 2,592 2,592 Furniture and fixtures 449 434 Equipment 17,694 16,812 Leasehold improvements 3,495 3,366 Breeding stock 117 36 Computer hardware and software 4,518 4,823 Construction and other assets in progress 1,240 1,829 30,269 30,056 Less: Accumulated depreciation and amortization (22,658) (21,457) Property, plant and equipment, net $ 7,611 $ 8,599

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows: Balance at December 31, 2021 $ 37,554 Impairment (482) Foreign currency translation adjustments (359) Balance at September 30, 2022 $ 36,713
Schedule of Intangible Assets	Intangible assets consist of the following as of September 30, 2022: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 75,129 $ (32,713) $ 42,416 Customer relationships 1,600 (1,600) — Trademarks 200 (200) — Total $ 76,929 $ (34,513) $ 42,416 Intangible assets consist of the following as of December 31, 2021: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 85,173 $ (32,882) $ 52,291 Customer relationships 1,600 (1,600) — Trademarks 200 (200) — Total $ 86,973 $ (34,682) $ 52,291

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	Long-term debt consists of the following: September 30, December 31, Convertible debt (1) $ 82,069 $ 179,882 Other — 52 Long-term debt 82,069 179,934 Less current portion 82,069 52 Long-term debt, less current portion $ — $ 179,882 (1) See Note 2 regarding adoption of ASU 2020-06 as of January 1, 2022.
Schedule of Components of Interest Expense	The components of interest expense related to the Convertible Notes were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cash interest expense $ 1,697 $ 1,750 $ 5,197 $ 5,250 Non-cash interest expense 338 3,011 934 8,641 Total interest expense $ 2,035 $ 4,761 $ 6,131 $ 13,891

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The following table presents the components of income tax benefit from continuing operations. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Current foreign income tax expense (benefit) from continuing operations $ — $ — $ (35) $ 7 Deferred income tax benefit from continuing operations (50) (61) (162) (180) Total income tax benefit from continuing operations $ (50) $ (61) $ (197) $ (173)

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	The components of accumulated other comprehensive (loss) income are as follows: September 30, December 31, Unrealized loss on investments $ (1,236) $ (331) Income (loss) on foreign currency translation adjustments (5,945) 534 Total accumulated other comprehensive (loss) income $ (7,181) $ 203

Share-Based Payments (Tables)

Share-Based Payments (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Costs	Stock-based compensation costs included in the condensed consolidated statements of operations are presented below: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of products $ 7 $ 8 $ 22 $ 23 Cost of services 15 25 63 103 Research and development 524 549 1,658 2,159 Selling, general and administrative 1,638 1,840 6,244 8,905 Discontinued operations (59) 68 9 272 Total $ 2,125 $ 2,490 $ 7,996 $ 11,462
Schedule of Stock Option Activity	Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2021 12,260,187 $ 14.06 6.79 Granted 4,322,890 2.23 Exercised (375) 2.28 Forfeited (544,928) 5.21 Expired (720,588) 23.44 Balances at September 30, 2022 15,317,186 10.60 7.28 Exercisable at September 30, 2022 8,715,518 13.77 5.84
Schedule of Restricted Stock Unit Activity	RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2021 468,481 $ 8.47 0.33 Granted 1,387,831 2.12 Vested (1,125,785) 4.29 Forfeited (32,712) 7.26 Balances at September 30, 2022 697,815 2.66 0.38

Operating Leases (Tables)

Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Components of Lease Costs	The components of lease costs were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Operating lease costs $ 600 $ 770 $ 1,840 $ 2,290 Short-term lease costs 53 48 155 141 Variable lease costs 84 185 308 623 Lease costs $ 737 $ 1,003 $ 2,303 $ 3,054 Other information related to operating leases in continuing operations was as follows: September 30, December 31, Weighted average remaining lease term (years) 6.15 6.72 Weighted average discount rate 11.06 % 10.94 % Nine Months Ended 2022 2021 Supplemental disclosure of cash flow information Cash paid for operating lease liabilities $ 1,877 $ 2,610 Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases) 466 4,868
Maturities of Lease Liabilities	As of September 30, 2022, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2022 $ 449 2023 2,084 2024 2,165 2025 2,129 2026 1,637 2027 1,246 Thereafter 3,109 Total 12,819 Present value adjustment (3,839) Total $ 8,980 Current portion of operating lease liabilities $ 1,041 Long-term portion of operating lease liabilities 7,939 Total $ 8,980

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Information by Reportable Segment	Segment Adjusted EBITDA by reportable segment was as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Biopharmaceuticals $ (12,417) $ (12,661) $ (35,286) $ (34,055) Exemplar 346 1,617 4,699 5,312 Segment Adjusted EBITDA for reportable segments $ (12,071) $ (11,044) $ (30,587) $ (28,743) Revenues by reportable segment were as follows: Three Months Ended September 30, 2022 Biopharmaceuticals Exemplar Total Revenues from external customers $ 14,624 $ 2,098 $ 16,722 Intersegment revenues — — — Total segment revenues $ 14,624 $ 2,098 $ 16,722 Three Months Ended September 30, 2021 Biopharmaceuticals Exemplar Total Revenues from external customers $ 129 $ 3,204 $ 3,333 Intersegment revenues 1,141 — 1,141 Total segment revenues $ 1,270 $ 3,204 $ 4,474 Nine Months Ended September 30, 2022 Biopharmaceuticals Exemplar Total Revenues from external customers $ 14,778 $ 10,368 $ 25,146 Intersegment revenues 1,446 — 1,446 Total segment revenues $ 16,224 $ 10,368 $ 26,592 Nine Months Ended September 30, 2021 Biopharmaceuticals Exemplar Total Revenues from external customers $ 723 $ 9,860 $ 10,583 Intersegment revenues 1,469 — 1,469 Total segment revenues $ 2,192 $ 9,860 $ 12,052
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Segment Adjusted EBITDA for reportable segments $ (12,071) $ (11,044) $ (30,587) $ (28,743) Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates 641 1,138 1,309 1,673 Add recognition of previously deferred revenue associated with upfront and milestone payments 14,561 1,163 16,007 1,849 Other expenses: Interest expense (2,036) (4,765) (6,137) (13,902) Depreciation and amortization (1,717) (2,029) (5,470) (6,174) Gain on disposals of assets — (13) — (6) Impairment losses — — (1,120) (543) Stock-based compensation expense (2,184) (2,422) (7,987) (11,767) Adjustment related to accrued bonuses paid in equity awards — — 1,698 — Equity in net gain (loss) of affiliates 862 — 861 (3) Other — (5) (105) (19) Unallocated corporate costs (5,744) (7,166) (24,718) (24,835) Eliminations (6) (1,237) (1,549) (1,812) Consolidated net loss from continuing operations before income taxes $ (7,694) $ (26,380) $ (57,798) $ (84,282)
Reconciliation of Revenue from Segments to Consolidated	The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Total segment revenues from reportable segments $ 16,722 $ 4,474 $ 26,592 $ 12,052 Elimination of intersegment revenues — (1,141) (1,446) (1,469) Total consolidated revenues $ 16,722 $ 3,333 $ 25,146 $ 10,583

Organization (Details)

Organization (Details)	Aug. 18, 2022
Discontinued Operations, Held-for-sale | Trans Ova
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest disposed of percentage	100%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Liquidity - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 31, 2018
Debt Instrument [Line Items]
Income (loss) from continuing operations, net of tax, attributable to parent	$ (57,601,000)
Net cash used in operating activities	(49,649,000)	$ (41,182,000)
Accumulated deficit	1,846,391,000		$ 1,915,556,000
Cash, cash equivalents, restricted cash, and short-term investments	153,770,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount	$ 82,440,000			$ 200,000,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Maximum risk of loss related to the identified VIEs	$ 0	$ 0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Net Loss Per Share - Additional Information (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	20,973,001	24,571,918	20,973,001	24,571,918
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,836,112	11,732,440	4,836,112	11,732,440
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	15,317,186	12,249,109	15,317,186	12,249,109
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	697,815	468,481	697,815	468,481
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	121,888	121,888	121,888	121,888

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net of current portion		$ 0		$ (179,882)
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net of current portion			$ (18,196)
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest			36,868
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective | Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest			$ 18,672
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective | Forecast
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Noncash interest expense	$ 11,800

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($)	3 Months Ended			9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Aug. 18, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses				$ 162,306,000	$ 0
Restricted cash		$ 82,443,000		82,443,000			$ 0
Gain (loss) on disposition of assets				(421,000)	(89,000)
Trans Ova | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest disposed of percentage						100%
Consideration						$ 170,000,000
Restricted cash		82,443,000		82,443,000
Gain (loss) on disposition of assets				(421,000)	(547,000)
Trans Ova | Discontinued Operations, Held-for-sale | Forecast | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses	$ 1,000,000
Trans Ova | Discontinued Operations, Held-for-sale | Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Earn-out payments (maximum)						10,000,000
Reimbursement limit						$ 5,750,000
MBP Titan | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of assets					464,000
Gain on lease termination					4,602,000
Gain from discontinued operations		$ 0	$ 60,000	$ 0	$ 4,599,000

Discontinued Operations - Carry

Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for Trans Ova (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents included in current assets held for sale	$ 0	$ 6,497
Discontinued Operations, Held-for-sale | Trans Ova
Assets
Cash and cash equivalents included in current assets held for sale		6,497
Trade receivables, net		19,491
Inventory		12,935
Other current assets		1,265
Property, plant and equipment, net		25,716
Intangible assets, net		1,824
Goodwill		16,594
Right-of-use assets		910
Other noncurrent assets		252
Total assets held for sale		85,484
Liabilities
Accounts payable		2,293
Accrued compensation and benefits		3,367
Other accrued liabilities		3,778
Deferred revenue		2,952
Current portion of long-term debt		350
Other current liabilities		111
Long-term debt, net of current portion		2,867
Other long-term liabilities		805
Total liabilities held for sale		$ 16,523

Discontinued Operations - Summa

Discontinued Operations - Summary of Financial Results for Trans Ova (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations	$ 95,023	$ (3,445)	$ 108,094	$ 16,977
Trans Ova | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	12,202	18,228	71,151	69,069
Cost of products	4,163	7,010	18,634	17,895
Cost of services	4,352	6,988	22,701	21,400
Research and development	481	486	2,348	1,367
Selling, general and administrative	3,204	7,683	15,215	17,162
Total operating expenses	12,200	22,167	58,898	57,824
Operating income (loss)	2	(3,939)	12,253	11,245
Other income, net	319	434	1,139	1,133
Gain on divestiture	94,702	0	94,702	0
Income (loss) before income taxes	95,023	(3,505)	108,094	12,378
Income tax (expense) benefit	0	0	0	0
Income (loss) from discontinued operations	95,023	(3,505)	108,094	12,378
Trans Ova | Discontinued Operations, Held-for-sale | Product revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	4,322	6,743	21,494	20,153
Trans Ova | Discontinued Operations, Held-for-sale | Service revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	$ 7,880	$ 11,485	$ 49,657	$ 48,916

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - Trans Ova (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Adjustments to reconcile net income to net cash used in operating activities
Depreciation and amortization	$ 9,044	$ 10,442
Gain on disposals of assets	421	89
Stock-based compensation expense	7,996	11,462
Provision for credit losses	944	1,219
Cash flows from investing activities
Purchases of property, plant and equipment	(4,871)	(4,474)
Trans Ova | Discontinued Operations, Held-for-sale
Adjustments to reconcile net income to net cash used in operating activities
Depreciation and amortization	3,574	4,268
Gain on disposals of assets	421	547
Stock-based compensation expense	9	272
Provision for credit losses	944	1,035
Cash flows from investing activities
Purchases of property, plant and equipment	(3,529)	(2,731)
Proceeds from sale of assets	$ 594	$ 1,425

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Financial Results for MBP Titan (Details) - MBP Titan - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Operating gain		$ 60,000		$ 4,599,000
Operating gain		60,000		4,599,000
Gain from discontinued operations	$ 0	$ 60,000	$ 0	$ 4,599,000

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on disposals of assets	$ 421	$ 89
Additional Cash Flow Elements, Investing Activities [Abstract]
Proceeds from sale of assets	$ 594	2,537
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment | MBP Titan
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on disposals of assets		(464)
Noncash gain on termination of leases		(4,602)
Additional Cash Flow Elements, Investing Activities [Abstract]
Proceeds from sale of assets		$ 1,083

Investments in Joint Ventures -

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	12 Months Ended
	Dec. 31, 2014 USD ($)	Sep. 30, 2022 board_seat	Dec. 31, 2021 USD ($)
Intrexon Energy Partners, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%
Maximum additional capital contribution committed	$ 25,000,000
Total number of seats on the joint venture's governing board | board_seat		5
Total number of seats on the joint venture's governing board, internally selected | board_seat		2
Total number of seats on the joint venture's governing board, externally selected | board_seat		3
Intrexon Energy Partners, LLC | Precigen And Remaining IEP Investors | Intrexon Energy Partners, LLC
Schedule of Equity Method Investments [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners		87.50%
Intrexon Energy Partners, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment			$ (428,000)
Intrexon Energy Partners, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%
Capital contributions	$ 25,000,000
Maximum additional capital contribution committed	25,000,000
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 25,000,000

Investments in Joint Ventures_2

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended	12 Months Ended
	Dec. 31, 2015 USD ($) board_seat	Dec. 31, 2015 USD ($) board_seat	Dec. 31, 2022	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Intrexon Energy Partners II, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%	50%
Maximum additional capital contribution committed	$ 10,000,000	$ 10,000,000
Total number of seats on the joint venture's governing board | board_seat	5	5
Total number of seats on the joint venture's governing board, internally selected | board_seat	1	1
Total number of seats on the joint venture's governing board, externally selected | board_seat	4	4
Intrexon Energy Partners II, LLC | Precigen And Remaining IEP Investors | Subsequent Event | Intrexon Energy Partners II, LLC
Schedule of Equity Method Investments [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners			2.90%
Intrexon Energy Partners II, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment				$ (435,000)	$ (435,000)
Intrexon Energy Partners II, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%	50%
Capital contributions		$ 18,000,000
Maximum additional capital contribution committed	$ 10,000,000	10,000,000
Intrexon Energy Partners II, LLC | All Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	$ 4,000,000
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value		$ 18,000,000

Investments in Joint Ventures_3

Investments in Joint Ventures - Interests in Intrexon Energy Partners and Intrexon Energy Partners II (Details)	1 Months Ended
	Jul. 31, 2022 USD ($)
Intrexon Energy Partners And Interxon Energy Partners II
Schedule of Equity Method Investments [Line Items]
Fair value, net asset (liability)	$ 0
Intrexon Energy Partners And Interxon Energy Partners II
Schedule of Equity Method Investments [Line Items]
Payments to acquire interest in joint venture	$ 7,000

Collaboration and Licensing R_3

Collaboration and Licensing Revenue - Narrative (Details) - USD ($)	1 Months Ended
	Jul. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, net of current portion, related party		$ 1,818,000	$ 23,023,000
Intrexon Energy Partners L.L. and Intrexon Energy Partners II, L.L.C
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, net of current portion, related party		$ 0	$ 21,205,000
Intrexon Energy Partners And Interxon Energy Partners II
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire interest in joint venture	$ 7,000

Collaboration and Licensing R_4

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 16,722	$ 3,333	$ 25,146	$ 10,583
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	14,561	22	14,561	389
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	3,768	0	3,768	0
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	10,793	0	10,793	0
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	0	18	0	371
Other | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 0	$ 4	$ 0	$ 18

Collaboration and Licensing R_5

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 1,894	$ 24,513
Long-term portion of deferred revenue	1,818	23,023
Current portion of deferred revenue	76	1,490
Collaboration and licensing agreements
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	1,818	23,023
Prepaid product and service revenues
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	52	1,277
Other
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 24	$ 213

Short-term and Long-term Inve_3

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 63,496	$ 121,133
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(1,236)	(331)
Aggregate Fair Value	62,260	120,802
U.S. government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	63,400	121,036
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(1,236)	(331)
Aggregate Fair Value	62,164	120,705
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	96	97
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 96	$ 97

Short-term and Long-term Inve_4

Short-term and Long-term Investments - Contractual Obligation, Fiscal Year Maturity (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due within one year	$ 62,260
After one year through two years	0
Total	$ 62,260

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 62,260	$ 120,802
Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	62,260	120,802
Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	62,164	120,705
U.S. government debt securities | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	62,164	120,705
U.S. government debt securities | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Certificates of deposit
Assets
Fair value of financial assets measured at fair value on a recurring basis	96	97
Certificates of deposit | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Certificates of deposit | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	96	97
Certificates of deposit | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Jul. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, interest rate, stated percentage	3.50%		3.50%
Fair value of convertible debt	$ 81,000	$ 160,000
Carrying value of convertible debt	$ 82,069	$ 179,882	$ 143,723

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Inventory	$ 219	$ 326
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	19	23
Livestock
Inventory [Line Items]
Inventory	$ 200	$ 303

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 164	$ 164
Buildings and building improvements	2,592	2,592
Furniture and fixtures	449	434
Equipment	17,694	16,812
Leasehold improvements	3,495	3,366
Breeding stock	117	36
Computer hardware and software	4,518	4,823
Construction and other assets in progress	1,240	1,829
Property, plant and equipment, gross	30,269	30,056
Less: Accumulated depreciation and amortization	(22,658)	(21,457)
Property, plant and equipment, net	$ 7,611	$ 8,599

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 564	$ 735	$ 1,833	$ 2,184

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Sep. 30, 2022	Sep. 30, 2021
Goodwill
Beginning balance	$ 37,554	$ 37,554
Impairment	$ (482)	(482)	$ 0
Foreign currency translation adjustments		(359)
Ending balance		$ 36,713

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Additional Information (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($) reporting_unit	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Segment Reporting Information [Line Items]
Impairment of goodwill		$ 482		$ 482	$ 0
Number of reporting units impaired | reporting_unit		1
Goodwill accumulated impairment losses	$ 14,483			14,483		$ 14,001
Amortization expense	$ 1,151		$ 1,315	$ 3,637	$ 3,990

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	$ 76,929	$ 86,973
Accumulated Amortization	(34,513)	(34,682)
Net	42,416	52,291
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	75,129	85,173
Accumulated Amortization	(32,713)	(32,882)
Net	42,416	52,291
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	1,600	1,600
Accumulated Amortization	(1,600)	(1,600)
Net	0	0
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	200	200
Accumulated Amortization	(200)	(200)
Net	$ 0	$ 0

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit - Exemplar Genetics, LLC - American State Bank - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	4%
Line of credit facility, outstanding balance	$ 0	$ 0

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Schedule of Long-Term Debt Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 82,069	$ 179,934
Less current portion	82,069	52
Long-term debt, less current portion	0	179,882
Convertible debt
Debt Instrument [Line Items]
Long-term debt	82,069	179,882
Other
Debt Instrument [Line Items]
Long-term debt	$ 0	$ 52

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended			9 Months Ended
	Nov. 09, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jul. 31, 2018 USD ($) day $ / shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Aug. 18, 2022 USD ($)	Jan. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Deferred income taxes				$ (162,000)	$ (180,000)
Long-term debt, net of current portion		$ 0		0				$ 179,882,000
Restricted cash						$ 200,000,000
Restricted cash, current		82,443,000		82,443,000				0
Gain on debt retirement				1,285,000	$ 0
Accrued interest		721,000		721,000
Convertible debt
Debt Instrument [Line Items]
Extinguishment of debt, amount		117,560,000
Gain on debt retirement		853,000
Subsequent Event | Convertible debt
Debt Instrument [Line Items]
Extinguishment of debt, amount	$ 26,400,000
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective
Debt Instrument [Line Items]
Long-term debt, net of current portion							$ 18,196,000
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective | Additional Paid-in Capital
Debt Instrument [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest							36,868,000
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 Retrospective | Accumulated Deficit
Debt Instrument [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest							$ 18,672,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount		$ 82,440,000	$ 200,000,000	$ 82,440,000
Proceeds from long-term debt, net of issuance costs			193,958,000
Debt issuance costs			$ 6,042,000
Debt instrument, interest rate, stated percentage		3.50%	3.50%	3.50%
Conversion rate			58.6622
Principal amount used in conversion			$ 1,000
Conversion price (in usd per share) | $ / shares			$ 17.05
Debt instrument redemption price, percentage			100%
Carrying value of convertible debt		$ 82,069,000	$ 143,723,000	$ 82,069,000				$ 179,882,000
Equity component of convertible debt, net of issuance costs and deferred taxes			50,235,000
Deferred income taxes			$ 13,367,000
Effective interest rate on convertible notes		425%		425%
Convertible notes, unamortized discount and issuance costs		$ 371,000		$ 371,000
3.5% Convertible Notes Due 2023 | Minimum
Debt Instrument [Line Items]
Common stock price trading days | day			20
Common stock price consecutive trading days | day			30
Percentage of common share price over conversion price for conversion			130%
3.5% Convertible Notes Due 2023 | Maximum
Debt Instrument [Line Items]
Common stock price trading days | day			5
Common stock price consecutive trading days | day			5
Debt instrument redemption price, percentage			98%

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Schedule of Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Cash interest expense	$ 1,697	$ 1,750	$ 5,197	$ 5,250
Non-cash interest expense	338	3,011	934	8,641
Total interest expense	$ 2,035	$ 4,761	$ 6,131	$ 13,891

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Domestic
Operating Loss Carryforwards [Line Items]
Taxable loss	$ 44,300	$ (24,700)	$ 38,000	$ (82,200)
Operating loss carryforwards	818,000		818,000
Deferred tax assets, capital loss carryforwards	212,500		212,500
Research and development tax credits	11,700		11,700
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	64,200		64,200
Generated After 2017
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 603,000		$ 603,000

Income Taxes - Components of In

Income Taxes - Components of Income Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit from continuing operations			$ (162)	$ (180)
Continuing Operations
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit from continuing operations	$ (50)	$ (61)	(162)	(180)
Total income tax benefit from continuing operations	(50)	(61)	(197)	(173)
Continuing Operations | Foreign
Operating Loss Carryforwards [Line Items]
Current income tax expense from continuing operations	$ 0	$ 0	$ (35)	$ 7

Shareholders' Equity - Issuance

Shareholders' Equity - Issuances of Precigen Common Stock (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Jan. 31, 2021	Sep. 30, 2021
Equity [Abstract]
Shares issued (in shares)	17,250,000
Shares issued during the period, value	$ 121,045	$ 121,045

Shareholders' Equity - Share Le

Shareholders' Equity - Share Lending Agreement (Details)	1 Months Ended
	Jul. 31, 2018 $ / shares shares
Equity [Abstract]
Borrowed shares, number issued (in shares) | shares	7,479,431
Share lending agreement, length of time for shares to be returned upon termination	5 days
Borrowed shares, public offering price per share (in usd per share) | $ / shares	$ 13.37

Shareholders' Equity - At-the-M

Shareholders' Equity - At-the-Market Sales Agreement (Details)	Aug. 09, 2022 USD ($)
Maximum
Subsidiary, Sale of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 100,000,000

Shareholders' Equity - Componen

Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ 142,532	$ 55,653	$ 107,348	$ 131,247	$ 159,196	$ 67,174
Total accumulated other comprehensive (loss) income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	(7,181)	$ (4,556)	203	$ 1,515	$ 2,541	$ 3,997
Unrealized loss on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	(1,236)		(331)
Income (loss) on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ (5,945)		$ 534

Share-Based Payments - Schedule

Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ 2,125	$ 2,490	$ 7,996	$ 11,462
Cost of products
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	7	8	22	23
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	15	25	63	103
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	524	549	1,658	2,159
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	1,638	1,840	6,244	8,905
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ (59)	$ 68	$ 9	$ 272

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly compensation, in the form of equity		$ 200
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lock-up period		3 years
Yearly compensation, payable in cash or equity	$ 100
Share-based Payment Arrangement, Option | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual stock option grant, grant date fair value	250
Restricted stock units | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual RSU grant, grant date fair value	$ 250
Share-based compensation arrangement by share-based payment award, award vesting period	1 year
Selling, general and administrative | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense for certain compensation arrangements			$ 63	$ 76	$ 558	$ 585
Precigen Stock Option Plan 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			0		0
Options outstanding (in shares)			14,843		14,843
Precigen Stock Option Plan 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			12,833,550		12,833,550
Options outstanding (in shares)			13,404,135		13,404,135
Number of shares authorized for issuance (in shares)			37,000,000		37,000,000
RSUs outstanding (in shares)			82,055		82,055
Precigen Stock Option Plan 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			7,243,025		7,243,025
Options outstanding (in shares)			1,898,208		1,898,208
Number of shares authorized for issuance (in shares)			12,000,000		12,000,000
RSUs outstanding (in shares)			615,760		615,760

Share-Based Payments - Schedu_2

Share-Based Payments - Schedule of Stock Option Activity (Details) - Precigen Stock Option Plans - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Shares
Balances at beginning of period (in shares)	12,260,187
Granted (in shares)	4,322,890
Exercised (in shares)	(375)
Forfeited (in shares)	(544,928)
Expired (in shares)	(720,588)
Balances at end of period (in shares)	15,317,186	12,260,187
Exercisable at end of period (in shares)	8,715,518
Weighted Average Exercise Price
Balances at beginning of period (in usd per share)	$ 14.06
Granted (in usd per share)	2.23
Exercised (in usd per share)	2.28
Forfeited (in usd per share)	5.21
Expired (in usd per share)	23.44
Balances at period end (in usd per share)	10.60	$ 14.06
Exercisable, weighted average exercise price, at end of period (in usd per share)	$ 13.77
Weighted Average Remaining Contractual Term (Years)
Balances, weighted average remaining contractual period	7 years 3 months 10 days	6 years 9 months 14 days
Exercisable at period end, weighted average remaining contractual period	5 years 10 months 2 days

Share-Based Payments - Schedu_3

Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - Precigen Stock Option Plans - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Restricted Stock Units
Balances at beginning of period (in shares)	468,481
Granted (in shares)	1,387,831
Vested (in shares)	(1,125,785)
Forfeited (in shares)	(32,712)
Balances at end of period (in shares)	697,815	468,481
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 8.47
Granted (in usd per share)	2.12
Vested (in usd per share)	4.29
Forfeited	7.26
Balances at end of period (in usd per share)	$ 2.66	$ 8.47
Additional Information
Weighted Average Remaining Contractual Term (Years)	4 months 17 days	3 months 29 days

Operating Leases - Additional I

Operating Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	8 years

Operating Leases - Components o

Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease costs	$ 600	$ 770	$ 1,840	$ 2,290
Short-term lease costs	53	48	155	141
Variable lease costs	84	185	308	623
Lease costs	$ 737	$ 1,003	$ 2,303	$ 3,054

Operating Leases - Maturities o

Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 449
2023	2,084
2024	2,165
2025	2,129
2026	1,637
2027	1,246
Thereafter	3,109
Total	12,819
Present value adjustment	(3,839)
Total	8,980
Current portion of lease liabilities	1,041	$ 1,393
Long-term portion of operating lease liabilities	$ 7,939	$ 8,747

Operating Leases - Lease Terms

Operating Leases - Lease Terms and Discount Rates (Details)	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted average remaining lease term (years)	6 years 1 month 24 days	6 years 8 months 19 days
Weighted average discount rate	11.06%	10.94%

Operating Leases - Other Inform

Operating Leases - Other Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Supplemental disclosure of cash flow information
Cash paid for operating lease liabilities	$ 1,877	$ 2,610
Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases)	$ 466	$ 4,868

Commitments and Contingencies -

Commitments and Contingencies - Contingencies - Additional Information (Details) $ in Thousands	1 Months Ended
	Jul. 31, 2022 USD ($)
Intrexon Energy Partners And Interxon Energy Partners II
Loss Contingencies [Line Items]
Payments to acquire interest in joint venture	$ 7

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Third Security, LLC
Related Party Transaction [Line Items]
Expense for services	$ 43	$ 25	$ 89
Sublease rental income	$ 21		$ 61
Third Security, LLC | Executive Chairman
Related Party Transaction [Line Items]
Ownership interest		100%

Segments - Adjusted EBITDA by R

Segments - Adjusted EBITDA by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (12,071)	$ (11,044)	$ (30,587)	$ (28,743)
Biopharmaceuticals
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	(12,417)	(12,661)	(35,286)	(34,055)
Exemplar
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ 346	$ 1,617	$ 4,699	$ 5,312

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (12,071)	$ (11,044)	$ (30,587)	$ (28,743)
Other expenses:
Depreciation and amortization			(9,044)	(10,442)
Gain on disposals of assets			(421)	(89)
Stock-based compensation expense	(2,125)	(2,490)	(7,996)	(11,462)
Equity in net income (loss) of affiliates			861	(3)
Other			(105)	0
Consolidated net loss from continuing operations before income taxes	(7,694)	(26,380)	(57,798)	(84,282)
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	641	1,138	1,309	1,673
Operating segments | Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	14,561	1,163	16,007	1,849
Corporate And Reconciling Items
Other expenses:
Interest expense	(2,036)	(4,765)	(6,137)	(13,902)
Depreciation and amortization	(1,717)	(2,029)	(5,470)	(6,174)
Gain on disposals of assets	0	(13)	0	(6)
Impairment losses	0	0	(1,120)	(543)
Stock-based compensation expense	(2,184)	(2,422)	(7,987)	(11,767)
Adjustment related to accrued bonuses paid in equity awards	0	0	1,698	0
Equity in net income (loss) of affiliates	862	0	861	(3)
Other	0	(5)	(105)	(19)
Unallocated corporate costs
Other expenses:
Consolidated net loss from continuing operations before income taxes	(5,744)	(7,166)	(24,718)	(24,835)
Eliminations
Other expenses:
Consolidated net loss from continuing operations before income taxes	(6)	(1,237)	(1,549)	(1,812)
Segment Adjusted EBITDA for reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for reportable segments	$ (12,071)	$ (11,044)	$ (30,587)	$ (28,743)

Segments - Revenues by Reportab

Segments - Revenues by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenues from external customers	$ 16,722	$ 3,333	$ 25,146	$ 10,583
Total segment revenues from reportable segments
Segment Reporting Information [Line Items]
Revenues	16,722	4,474	26,592	12,052
Operating segments
Segment Reporting Information [Line Items]
Revenues from external customers	16,722	3,333	25,146	10,583
Revenues	16,722	4,474	26,592	12,052
Operating segments | Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues from external customers	14,624	129	14,778	723
Revenues	14,624	1,270	16,224	2,192
Operating segments | Exemplar
Segment Reporting Information [Line Items]
Revenues from external customers	2,098	3,204	10,368	9,860
Revenues	2,098	3,204	10,368	9,860
Intersegment revenues
Segment Reporting Information [Line Items]
Revenues	0	1,141	1,446	1,469
Intersegment revenues | Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues	0	1,141	1,446	1,469
Intersegment revenues | Exemplar
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Elimination of intersegment revenues
Segment Reporting Information [Line Items]
Revenues	$ 0	$ (1,141)	$ (1,446)	$ (1,469)

Segments - Additional Informati

Segments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Exemplar
Segment Reporting Information [Line Items]
Percentage of revenue attributable to customer	41.10%	75.60%	62.40%	60.70%
Non-US
Segment Reporting Information [Line Items]
Long-lived assets	$ 3,122		$ 3,122		$ 4,463
Revenues	$ 63	$ 93	$ 217	$ 296

Uncategorized Items - pgen-2022

Label	Element	Value
Restricted Cash and Cash Equivalents, Noncurrent	us-gaap_RestrictedCashAndCashEquivalentsNoncurrent	$ 423,000